3 Things You Need to Know If You Buy Intuitive Surgical Today

Source Motley_fool

Key Points

  • Intuitive Surgical is at the cutting edge of surgery, with a still-growing base of surgical robots in the market.

  • Services and parts are far more important to the company's business today than selling new robots.

  • The stock price is more attractively priced than it has been in recent years.

  • 10 stocks we like better than Intuitive Surgical ›

Intuitive Surgical (NASDAQ: ISRG) is a growth stock, hailing from the medical-device segment of the broader healthcare sector. It makes the da Vinci surgical robot system, which is one of the leading choices for surgical robotics.

The company's stock price is down around 30% from its 52-week high, so now could be a good time to consider buying Intuitive Surgical. Here are three things to know if you're looking to add it to your portfolio.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »

A hand building a puzzle vertically.

Image source: Getty Images.

1. Intuitive Surgical is at the cutting edge (and growing)

Using the words "cutting edge" is a bit of a pun, but given Intuitive Surgical's focus on surgical robots, the subhead above is true. The medical-device maker was one of the first to commercialize this technology.

Surgical robots make surgery safer, but they also can allow for better patient outcomes because they're often less invasive than other options. The technology has interesting long-term appeal, as well.

For example, a robot could be located in one country, while the operator could be located in another. That would give the healthcare industry the ability to provide world-class care anywhere a surgical robot is located. This is why, despite Wall Street's currently dour view of the healthcare stock, Intuitive Surgical is still selling plenty of da Vinci systems.

For example, in the second quarter of 2025, the company placed 395 new systems into service, up from 341 in the year-ago period. The total number of da Vinci systems is now 10,488, up 14% from a year ago, and the number of procedures the company's surgical robots performed increased 17% year over year.

In other words, there's still a growth story here. Sure, it gets more difficult to grow the installed base as more and more da Vinci robots get deployed -- that's just how things work. However, the growth story isn't over, even though Wall Street is downbeat on the stock.

2. The big money isn't in the robots

The installed base of da Vinci robots is really important, and it's good that the numbers keep rising. But the real business here isn't actually selling the robots anymore. In fact, robots make up a little less than 25% of the top line of the company's income statement. That's not really surprising when you consider the way the robots are used.

Surgery requires the use of many consumable items that have to be replaced after every procedure or at least regularly. That's not any different because a da Vinci robot is being used. That's why parts (the line item on the income statement is technically "Instruments and accessories") make up roughly 60% of Intuitive Surgical's sales. The rest of the top line is services, which is basically installation and maintenance of da Vinci systems.

Both of these revenue sources are like annuities for Intuitive, because they generate recurring income. It's important to monitor the growth in the installed base, but the real story is the beneficial impact it has on the parts and services revenue that Intuitive Surgical generates over time.

3. The stock is cheaper than it has been

A value investor isn't likely to find Intuitive Surgical attractive, noting that its price-to-sales ratio (P/S) is a lofty 17x or so and the price-to-earnings ratio (P/E) is also high at nearly 60x. On an absolute basis, Intuitive Surgical is a pricey stock. However, if you have a growth stock bias, you might still want to take a look.

ISRG Chart

Data by YCharts.

The company's five-year average price-to-sales ratio is around 18.6x. The longer-term average price-to-earnings ratio is roughly 72.5x. The recent pullback in the growing business has left the stock's valuation lower than it has been in a while. It isn't cheap, but it is cheaper, which might interest more aggressive investors. If you look back historically, a drawdown of the current size (roughly 30%) isn't actually all that unusual (see chart above).

Not for the squeamish, but a potential opportunity

A stock with a 60x P/E ratio is going to be appropriate for a relatively small set of investors. You'll need to believe that Intuitive Surgical's business is still growing its installed base -- which it is -- and that the installed base will lead to material recurring revenue -- which so far it has.

You'll also need to believe that a 60x P/E ratio is attractive, which the five-year average 72.5x P/E ratio suggests it may be, relatively speaking. All in, for more aggressive growth investors, Intuitive Surgical could be worth a deep dive right now.

Should you invest $1,000 in Intuitive Surgical right now?

Before you buy stock in Intuitive Surgical, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Intuitive Surgical wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $657,412!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,154,376!*

Now, it’s worth noting Stock Advisor’s total average return is 1,075% — a market-crushing outperformance compared to 190% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of October 13, 2025

Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Intuitive Surgical. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Samsung Electronics Forecasts Stronger-Than-Expected Q3 Profit on AI Demand Samsung forecasts Q3 profit of 12.1 trillion won, boosted by strong AI chip demand.
Author  Mitrade
Yesterday 01: 43
Samsung forecasts Q3 profit of 12.1 trillion won, boosted by strong AI chip demand.
placeholder
Dollar Gains as US-China Trade Tensions Ease The U.S. dollar remained steady on Tuesday following a shift in President Donald Trump’s harsh stance on tariffs against China.
Author  Mitrade
Yesterday 01: 38
The U.S. dollar remained steady on Tuesday following a shift in President Donald Trump’s harsh stance on tariffs against China.
placeholder
Asian Stocks Mixed as Commodities Pause and Yen Draws AttentionAsian equity markets struggled to close the week on a weak note Friday, influenced by ongoing losses on Wall Street that extended into early Asian trading.
Author  Mitrade
Oct 10, Fri
Asian equity markets struggled to close the week on a weak note Friday, influenced by ongoing losses on Wall Street that extended into early Asian trading.
placeholder
Oil Prices Hold Steady Amid Gaza Ceasefire and US Sanctions Oil prices held steady in early Asian trading on Friday following the announcement of a ceasefire between Israel and Hamas.
Author  Mitrade
Oct 10, Fri
Oil prices held steady in early Asian trading on Friday following the announcement of a ceasefire between Israel and Hamas.
placeholder
Bitcoin drops below $110K ahead of $22B options expiry; altcoins tumbleBitcoin fell below the $110,000 mark on Friday, heading for a steep weekly loss as nearly $22 billion in cryptocurrency options were set to expire. The drop also comes as traders await key U.S. inflation data that could influence the Federal Reserve’s policy outlook.
Author  Mitrade
Sept 26, Fri
Bitcoin fell below the $110,000 mark on Friday, heading for a steep weekly loss as nearly $22 billion in cryptocurrency options were set to expire. The drop also comes as traders await key U.S. inflation data that could influence the Federal Reserve’s policy outlook.
goTop
quote